Life Sciences Archive » August, 2016

Life Sciences - August, 2016

351 articles

• Medtronic Asks 9th Circ. To Flip $15M Loss In Device Trial
• Theranos Yanks New Zika Blood Test
• NY County Sues Drug Cos. Over Opioid Marketing
• Procter & Gamble Gets Bulk Of Fixodent MDL Cases Tossed
• 3 Takeaways From FDA's Off-Label Forum Plan
• Avalanche Aims To Ditch IPO Suit Over Eye Drug
• Convicted Ex-Acclarent Execs Shed Bail, Travel Requirements
• U. Of Minn. Says Gilead's $20B Hep C Drugs Flout Patent
• 2 Firms Grab Spotlight Amid Quiet August For IPOs
• Ohio Getting Closer To Authorizing Atty Medical Pot Work
• DC Circ. Ruling Dangerous For Hatch-Waxman: Takeda
• ITC Won't Appeal ClearCorrect Patent Ruling To High Court
• Lack Of Diligent Search Bars 2nd AIA Petition, PTAB Says
• HeartWare Says Investor Suit Over FDA Regs Is 'Opportunistic'
• FDA Adds Black Box Warnings About Mixing Opioids, Benzos
• Blood Sugar Monitor Maker Hit With Suit Over Car Crash
• Final Bellwether Trials Picked In Syngenta Tainted Seed MDL
• Abbott Calls Alere's $5.8B Merger Suit 'Publicity Stunt'
• 'Plain Language' Bars Pfizer's $8.3M Tax Suit, Gov't Says
• Reconciling The Practice With The Business Of Law
• Plavix Ruling Cements Calif. As Center For Mass Torts
• Celgene Battles $40B FCA Suit Over Off-Label Promos
• FDA Clears Sandoz Biosimilar Of Amgen's Enbrel
• AstraZeneca Will Pay $5.5M To SEC Over FCPA Claims
• Endo Vitamin Buyers Reach $15.5M Settlement Agreement
• FDA Warning Wire: Drugmaker VP Removed During Inspection
• Pfizer Wins Dismissal Of Zoloft Birth Defects Suit
• Merck Patent For Contraceptive NuvaRing Nixed As Obvious
• Actavis Wants Conspiracy Claim Nixed In Testosterone MDL
• Chicago Supplement Biz In FDA Hot Water Over Lead Levels
• In Search Of Objective Evidence Success At PTAB
• REBUTTAL: Establishing Standards And Norms In Mediation
• Calif. High Court Greenlights Non-Residents' Plavix Suits
• Trans Ova Says Halo Doesn't Reopen Sex-Selection IP Suit
• Otsuka Can't Duck Antitrust Claims Over Antipsychotic Drug
• NJ Pharma Co. Can't Revive Antitrust Suit Over Cough Syrup
• St. Jude Heart Devices Have Security Weaknesses, Suit Says
• Shire Seeks Toss Of Fortis Bid For $425M Drug Study Payout
• Pharma Co.'s Supply Chain Lies Caused Stock Drop, Suit Says
• GSK Can't Ax Out-Of-Staters From Ill. Paxil Suit, Court Says
• Icahn Boosts Herbalife Stake In Ongoing Battle With Ackman
• Convicted Ex-Acclarent Execs Don't Need Passports: DOJ
• Judge Rethinks Remand Of Mo. Residents' Benicar Claims
• Funding Litigation And Treatment: Leveling The Playing Field?
• Martin Shkreli Sells Remaining Stake In KaloBios
• Don't 'Discount' Gov't Opinion On Anti-Kickback Exception
• Brazilian Agency's Help In Lilly Coverage Row OK, Arch Says
• Mylan To Release $300 EpiPen Generic After Backlash
• DaVita Seeks End To Dialysis Suit
• Third-Party Payors Say GSK Skews Avandia Claims
• Health Hires: K&L Gates, Pharma Trade Org, Tucker Ellis
• Theranos To Appeal Sanctions Over Lab Lapses
• Deals Rumor Mill: Herbalife, Hurtigruten, China Vanke
• Alere Drags Abbott To Court In Bid To Force $5.8B Deal
• St. Jude Insists Cardiac Devices Are Safe From Cyberattacks
• FDA Wants Blood Donations Tested For Zika Nationally
• Globus Investor Suit Lacked 'Factual Allegations,' Judge Says
• Defining Attorney-Client Relationships In The Electronic Age
• Aveo Promises Reforms In Cancer Drug Derivative Settlement
• Taxation With Representation: Ropes, Cooley, Wachtell
• Exclusion Axes Anda's 'Pill Mill' Coverage, 11th Circ. Says
• FCA Attys Clash Over Escobar Test For Implicit Compliance
• Gilead, Emory Drop HIV Drug Generic Suit
• The Complexity Of Trademarks In The Marijuana Business
• $3.5B Auspex-Teva Merger Challenge Axed By Chancery
• St. Jude Cardiac Devices Carry Cyberattack Risk, Report Says
• FTC Wins Access To AndroGel Docs In AbbVie Antitrust Suit
• PTAB Won't Let Broad Seek CRISPR Docs From Fenwick
• Roxane Infringed Vanda's Antipsychotic Patent, Judge Rules
• E-Textiles: Regulating The Future Of Fashion
• Ill. AG Slams Insys Over Opioid Off-Label Marketing
• Real Estate Rumors: McKesson, Fla. Crystals, McSam Hotel
• 4 Reasons Law Firm Business Development Initiatives Fail
• Latham-Led Novan Files $60M IPO To Boost Acne Drug
• PE-Backed IBA Molecular Pays $690M For Nuclear Imaging Biz
• Mylan's Changes To EpiPen Prices A 'PR Fix,' Senator Says
• PTAB Scraps 2 Teva Copaxone Drug Patents After Review
• Calif. Theranos Actions Combined Into Single Suit
• Drugmaker MannKind Beats Shareholder Securities Suit
• DOJ Gets Kickback Case Revived Against Medical Supplier
• Clinton, AMA Join Backlash Against EpiPen Price Hikes
• Canada, Lilly Make Last Pleas In Patent Policy NAFTA Row
• Medicare Settlements In Tainted Steroids MDL Get Early OK
• Actavis Uses Nautilus To Ax Claims In Horizon Pennsaid Case
• Drugmaker Had Too Much Control To Duck $6M Tax Deficiency
• Express Scripts Must Face Pharmacies' Antitrust Claims
• Toronto Exchange Owner Funds New Tech Growth Group
• Zydus Can't Escape Wrongful Death Suit, Judge Says
• Cephalon, Sagent Ink Deal In Generic Cancer Drug Fight
• Dexcom Suit Says It's Not Poaching InSpark Glucose Patents
• Omnicare Can't Kick Whistleblower's $421M FCA Suit
• 3rd Circ. Backs Bigger Damages For Infringement Of Rare Pics
• Prolias Suit Against PDI Tossed For Not Getting New Counsel
• Lilly Fights Brazilian Agency Wading Into Arch Squabble
• FTC Alums: Retail Mergers Reflect New Approaches At FTC
• Ropes & Gray Leads Pfizer In Deal For AstraZeneca Unit
• Pay-For-Delay & Stock Prices: Smoking Gun Or Damp Squib?
• Rainmaker Q&A: Duane Morris' Matthew Taylor
• Turing Exec Says Punishment Followed Sex Assault Inquiry
• Boston Judge Leans Toward Remanding La. GranuFlo Case
• Judge Nixes Eli Lilly's Axiron Patents In Win For Generics
• 'Permissive' USPTO Patent Policies Raise Drug Prices: Study
• FDA Warning Wire: Aloe Vera Farm Gets Agency Burn
• Genentech Seeks Quick Win In Cancer Drug Dosage Case
• Kasowitz Benson Says Chem Cos. Hid Risks, Owe Billions
• 9th Circ. Affirms Arbitration For 23andMe In Marketing Case
• R&D Impact May Be Key In Scrutiny Of Pfizer Oncology Deal
• Cinven Shells Out $1.4B For PE-Backed BioClinica
• Proposed Class Action Over 'Organic' Baby Food Tossed
• Eli Lilly Urges 9th Circ. Not To Revive Cymbalta Suit
• Transport Cos. Shake Claims In $9M Drug Theft Dispute
• Warner Says Aggrenox Court Erred In Pay-For-Delay Case
• DLA Piper Attys Say Insurer's Sanctions Bid Distorts Record
• From BigLaw To Your Own Firm: 4 Tips For Legal Startups
• FTC Alums: 5 Institutional Challenges For The FTC
• Rainmaker Q&A: Sills Cummis' Beth Rose
• NJ Reglan Ruling Widens Generic Label Preemption Split
• Judge Explains Rulings In Acclarent Criminal Cases
• Inside Sanofi's Failed $9.3B Pursuit Of Medivation
• Investor Agrees To Drop FedEx Drug Shipping Derivative Suit
• Nebraska Couple's Reglan Claims Time-Barred, Judge Says
• Deals Rumor Mill: Empresas, Renesas Electronics, Cinven
• Senator Asks FTC To Investigate Mylan's EpiPen Price Soar
• Colo. Dispensary Moves For Refund In Marijuana Tax Row
• Biotech Asks Full Circ. To Resolve Patent Review Conflict
• Nestle And Galderma Hit Perrigo With IP Suit Over Generic
• 3 Companies Reboot IPO Pipeline With $255M In New Filings
• Medline Hit With NJ Suit Over Burning Dangers Of Cold Pack
• 4 Communications Fundamentals For High-Stakes Litigation
• Revolutionizing UK Product Recall Action?
• FTC Alums: SMARTER Changes To FTC Merger Reviews
• Reglan Suits Not Preempted By Federal Law, NJ Justices Say
• Pfizer Wins Over Medivation With $14B Buyout
• Respecting The Rules For Searching Jurors' Social Media
• Ethicon's Noncompete Claim Can't Beat Calif. Law, Suit Says
• Lipitor Buyers Say Claims Can't Be Axed Before Discovery
• Texas Jury Clears Spinal Device Co. In Patent Suit
• Wipeout Of Mirena MDL To Be Challenged At 2nd Circ.
• Sheppard Mullin Adds Crowell & Moring Gov't Contracts Pro
• SEC Blasts Stay Bid Pending High Court Action In Salman
• Surgery Center Objects To Remand Bid In Meningitis MDL
• Sequenom Investor Wants Tender Offer Halt In LabCorp Buy
• FDA Barred From Shutting Down Tissue Therapy Co.
• Insurance Co. Fights Sanctioned DLA Atty Testimony Request
• Abilify Whistleblowers Want 6th Circ. To Revive FCA Suit
• FDA Needs Plan To Regulate Clinical Software, Group Says
• Class Attys Seek $1.5M Fee On $5.4M Shareholder Gain
• 'Schwarzenegger' Supplement Maker Defends Protein Claims
• J&J Fights $500K Risperdal Verdict At Pa. Appeals Court
• Deals Rumor Mill: Wako Pure Chemical, Vale, Starwood
• Greenland Venture Buys 42-Acre South San Francisco Site
• FTC Alums: Focusing On The FTC With 2020 Vision
• Meningitis Victim Statements Barred At Investor's Sentencing
• Risk Management Tips For Attys Serving As Local Counsel
• Ex-Novartis Worker's Suit Tossed For Deceiving NJ Court
• Steamfitters Funds Chosen To Lead Endo Class Action
• Pentair To Net $3.15B In Sale Of Valves Business To Emerson
• Pfizer Ducks Lipitor Fraud Claims Suit Again In 2nd Circ.
• MRI Patent Suit Tests Bounds Of Williamson
• 9th Circ. Remands Diabetes Suit Instead Of Dismissing
• Ex-Acclarent Execs Want Travel Restrictions Lifted
• 'Nothing Nefarious' About Alleged Kickbacks, Supplier Says
• T. Rowe, Alleghany Go After Valeant For Stock Drop
• Deals Rumor Mill: Illumina, Rentex, Clover Technologies
• Ohio High Court To Review Attys' Services To Marijuana Cos.
• Washington Must Pay For State Employees' Hep C Treatment
• Bayer, Global Product VP Hit With Gender Bias Suit In NJ
• Ex-Insys Staffers Plead Not Guilty In Opioid Kickback Suit
• Patent Term Extension Not A 1-Trick Pony For Animal Drugs
• DTSA — New Strategy For 'Bring Your Own Cloud' Issues
• Dorsey Backs Away From Controversial Shkreli Invite
• Sanctioned DLA Piper Atty Raises Doubts On Key Testimony
• Eli Lilly Subsidiary Gets $3.9M In Fees Under Octane Ruling
• Costco, Apotex Generic Lipitor Labeling Suit Hits 9th Circ.
• Shkreli Seeks Escape From KaloBios Securities Litigation
• Dusek Doesn't Bar Merck Investors' Claims, 3rd Circ. Hears
• IKOR, Execs Denied New Trial, But Get Damages Slashed
• Hyland's Beats Remaining Claims After False Ad Suit Verdict
• Janssen Loses Fight To Keep Remicade Patent In Force
• 5th Circ. Upholds Dismissal Of Faulty Spinal Implant Suit
• Beware The 'Standard' Mediation Confidentiality Agreement
• Deals Rumor Mill: Wako Pure Chemical, MSG, Brookfield
• Pfizer Says $8.3M Tax Interest Row Belongs In NY Court
• Equistone Partners Buys Into German Peroxide Chemicals Co.
• CVC To Exit Chemical Co Univar In $398M Stake Sale
• 9th Circ. Affirms Toss Of NuBone Safety Claims
• Janssen Faces Mixed Prospects In Immuno Drug IP Suit
• Sequenom Investors Sue To Block LabCorp Takeover Bid
• Suboxone Maker Says Docs Are Withheld In Product-Hop MDL
• Invalidity Of Bovine Sperm Patent Is Bull, Court Told
• Ex-Pfizer Doc Asks Court To Rethink His Fraud Claims Suit
• PeriCor Asks Judge To Nix 'Biased' Merck Arbitration Award
• FDA Warning Wire: A Midsummer Enforcement Bonanza
• Rutgers Wants BioArray IP Licensing Suit Back In State Court
• UCB's Anti-Convulsant Patent Is Valid, Delaware Judge Rules
• Ky. AG Hits J&J With Pelvic Mesh Deceptive Marketing Suit
• Seeger Weiss Immune From $6.9M Vioxx Row, 5th Circ. Told
• Pfizer Unit's Patent For Antibiotic Drug OK'd By Fed. Circ.
• Arch Seeks Brazilian Insurance Regulator's Aid In Lilly Row
• Swiss Biotech Lonza Pays Up To $300M For Ingredients Maker
• 5 Mistakes To Avoid When Building Law Libraries
• Bovine Sperm Monopoly Still Wins $2M Patent Verdict
• PTAB Again Upholds Verinata Patent After Fed. Circ. Remand
• Cipro Buyers Want OK For $100M Pay-For-Delay Settlement
• Express Scripts Investor Demands Look At Books, Records
• FTC Wins False Ad Case Against Gray Hair Supplement Maker
• FDA's Abilify Logic Invites 'Gamesmanship,' Otsuka Says
• BALCA Says Wage Range In Posting Doesn't Nix Labor Cert.
• New Trial Unlikely After $70M Neovasc Verdict, Judge Says
• Fed. Circ. Finds Pill-Dispensing Patent Valid Again
• Bristol-Meyers, Pfizer Hid Eliquis Risks, $10M Suit Alleges
• Rainmaker Q&A: Kilpatrick Townsend's Tina Williams McKeon
• DOJ, Defense Attys Brawl Over Escobar's FCA Impact
• Deciding Where To File Patents Internationally In 2016
• Law Students Should Explore BigLaw Pro Bono Options
• Does Your D&O Policy Cover Informal SEC Investigations?
• Drugmakers Hit With Suit Over Nerve-Damaging Antibiotic
• Medtronic Seeks To Nix State-Law Claims In FCA Suit
• Texas Court Revives UBS Shareholder Defamation Suit
• Gilead Says Indian Co. Is Infringing HIV Drug Patents
• Taxation With Representation: Fenwick, Sullivan, Gibson Dunn
• Judge Tacks $6M In Delay Damages To $70M Risperdal Award
• Health Hires: KDB, Rubin Add Scientists As IP Partners
• Ceragenix Wins Dismissal Of Ex-Exec's SOX Complaint
• Calif. Pair Faces Insider Trading Charges In Biotech Scheme
• Lab Affiliates Want Meningitis Victims Silent At Sentencing
• Abbott Must Hand Over Old Depositions In Whistleblower Suit
• Gilead Entitled To Fees Over Merck Misconduct, Judge Says
• Bard Again Slams Gore's 'Baseless' Sanctions Bid In IP Suit
• FTC Wins AndroGel Info From AbbVie In Antitrust Suit
• Bausch & Lomb Settles Eye Vitamin Patent Suit During Trial
• Hagens Berman Clients May Be Allowed To Drop GSK Claims
• Endo, Impax Face Leaner Opana Pay-For-Delay MDL
• Ancestry.com Wants 6th Circ. To Shut Down 'AncestryByDNA'
• Acella Escapes Skin Disorder Drugs Trade Secrets Suit
• Brother's Firm May Cause Judge DQ In Supplement MDL
• PE-Backed Medpace Soars Among 2 IPOs Totaling $251M
• Pre-AIA And Post-AIA Issues Presented By The On-Sale Bar
• Eli Lilly, Canada Spar Over $383M NAFTA Arbitration Claim
• Calif. Judge Rejects False-Ad Class Action Settlement
• Drug Co. Wins Deferral Treatment Of $2.8M Income Gain
• Ex-Hunton Attorney & Pal Charged With Insider Trading
• Novo Nordisk's $305M Campus Sale Sets NJ Record For 2016
• Daiichi, Forest Ask Judge To Rethink Benicar Mo. Remand
• 7th Circ. Tightens Standards For Disclosure-Only Deals
• Deals Rumor Mill: Jeld-Wen, Samsung, Entertainment One
• PE Owners Exit Zimmer Biomet In $965M Secondary Sale
• 3rd Circ. Pauses Trading Case Over SEC, Trader Objections
• Enviros Scold FDA Over Genetically Modified Mosquito Plan
• Fed. Circ. Upholds PTAB's Suboxone Patent Invalidation
• Pfizer Can Argue It Invented Cattle Treatment Before Bayer
• Sagent Hit With Investor Suit Over Proposed Merger
• Some Indirect Claims Stay In Aggrenox Pay-For-Delay Row
• 2 Cooley-Led Biotechs Price $920M In Follow-On Stock Sales
• Return Of Exec Accountability Creates Compliance Challenges
• Fed. Circ. Says PTAB Spinal Patent Ruling Needs Elaboration
• Novartis Korea Execs Indicted, Accused Of Bribing Docs
• FDA Warning Wire: Pfizer Hospira Plant Troubles
• Chicago Says Recent Decision Backs Opioid Marketing Suit
• Investor Claims Biopharma Withheld Patient Testing Info
• SynCardia Unsecured Creditors Dispute Secured Tort Liens
• Allergan Scores $58M Tax Break To Remain In NJ
• DOJ Says Judge Misread Kickback Exception In FCA Case
• 1st Circ. Told No Fraud Was Public Before Covidien FCA Suit
• NY Pharmacist Convicted In Black Market HIV Meds Scheme
• Writing Arbitration Clauses To Get The Arbitration You Want
• Fla. Drug Co. Recalls Liquid Products Over Bacteria
• FDA's Pursuit Of A National Medical Device Evaluation System
• Abbott Still Worried About Alere Pact Even After SEC Filing
• Medical Device Maker CVRx Nabs $113M In Financing
• Medical Scrub, Garment Maker Hit With False Advertising Suit
• EQT Buys Health Care Analytics Co. In $2.35B Deal
• Synthes Reaches $5M Proposed Settlement In Expenses Suit
• AstraZeneca Says Mylan Can't Sell Cancer Generic Till 2019
• Cephalon To Pay $125M To Settle Provigil Antitrust Litigation
• DC Circ. Won't Rehear Czech $325M Arbitration Fight
• Medical Tech-Focused BioVentures In Midst Of Raising $100M
• SEC, Insider Tell 3rd Circ. Not To Wait For Salman Ruling
• CR Bard Blasts Rival's 'Baseless' Sanctions Bid In IP Suit
• Express Scripts Says Claims In $15B Pricing Dispute Hold Up
• Biogen Escapes Negligence Suit Over MS Drug Labeling
• Bristol-Myers Directors Sued in NY Over FCPA Inaction
• NuScience Wants Brothers Jailed For Threats During IP Fight
• 9th Circ. Questions Validity Of NuBone Safety Claims
• AbbVie Hit With Hedge Fund's Suit Over Failed Shire Deal
• GSK May See Payor Exit Diabetes Drug Suit On Own Accord
• Genetically Modified Mosquitoes' Trial Run Inches Closer
• Taxation With Representation: Latham, Fenwick, Kirkland
• Hospira Can't Beat Amgen's Biosimilar Notice Suit
• Zoetis Says AX Pharmaceutical Imports Infringing Dog Drug
• Amgen's Humira Biosimilar Infringes 61 Patents, AbbVie Says
• Judge Narrows Case Against Doc In Fatal Meningitis Outbreak
• Fed. Circ. Hands Win to Supplement Co. In Patent Suit
• 4 Firms Poised To Steer IPOs Totaling $270M
• Deals Rumor Mill: Apollo Global, Nissan, Valeant
• Ex-Va. First Lady's Appeal Paused After High Court Reversal
• A Review Of Key Criminal Cases Against Execs In Q2
• Meningitis Victims Ask For Preliminary OK Of CMS Settlement
• U. Of Wash. Wins Trial Over Woman's Surgery Death
• Why High Court Hasn't Reviewed Structural Obviousness Test
• 3 Ways To Avoid Antitrust Issues When Launching A Redesign
• 9 Tips For Becoming A Legal Pundit In The Media
• Gilead's $15M Fee Bid On Table After Merck Witness' Lies
• Calif. State Judge Preserves Essure Injury Claims
• Liberty Off Hook For MusclePharm's $3M Indemnity Claim
• Doctor In Charge Of Drug Trial Accused Of Insider Trading
• US Chamber Challenges Anti-Tax Inversion Rule
• PTAB Knocks Out 2 Eli Lilly Cialis Patents In AIA Reviews
• NY AG Ends Noncompetes At Medical Information Company
• Law Firm Employees Can Better Defend Against Cyberthreats
• Surgery Center Calls 'Facts' In Meningitis Suit Irrelevant
• Whistleblowers Call Med Supplier's Discounts Kickbacks
• AIG Unit Asks 9th Circ. To Nix $3.7M Ad-Suit Coverage Ruling
• GSK, Actavis Dodge RICO Claims In Testosterone Case
• Judge Tosses Investors' Suit Over $140M ConforMIS IPO
• Former DOJ Officials Warn Against Bayer-Monsanto Merger
• PTAB Nixes Carnegie Mellon's Joint Placement Patent Claims
• Fed. Circ. Urged To Reverse PTAB Ruling On Opiate Treatment
• FDA's Biosimilar Labeling Vision Stirs Up Discord
• INC Research Investors Prime $210M Secondary Offering
• NY Firm Tells 11th Circ. Ex-Client Admitted To Owing Fees
• Allergy Test Maker Says Physician Antitrust Claims Off Base
• Shire, DOJ Reach $350M Deal In Dermagraft FCA Investigation
• J&J Wants Talc Trial Moved Due To Plaintiffs' Atty Ads
• FDA Warning Wire: Listeria Outbreak, 'Cosmeceuticals'
• AARP Urges 3rd Circ. To Revive Eye Drop Suit
• Deals Rumor Mill: Biogen, Aetna, Enbridge
• Pillsbury Nabs Corporate Transaction Pro From DLA Piper
• SynCardia Gets Nod For DIP Loan, $19M Auction Plan
• No Need For Hearing Vetting Suicide Expert, Atty's Widow Says
• Ex-Acclarent Execs Want Misdemeanor Convictions Tossed
• Pfizer To Pay $486M To Settle Celebrex, Bextra Securities MDL
• Fed. Circ. Clarifies The Test For Patentable Subject Matter
• FDA Streamlines Reviews Of Next Generation Sequencing Tests
• State-Of-The-Art Defense And The Internet Of Things
• SynCardia May Pivot To Private Bankruptcy Sale
• J&J Unit, Surgeon Owe Millions For Woman's Death, Jury Told
• Mirena MDL Shows How A Lack Of Experts Can Doom A Case
• FTC Urges Quick Ruling On Lidoderm, Opana Severance Bid
• Advent Takes 50% Stake In Biopharma Services Co. InVentiv
• J&J Unit Reaches Settlement In Tylenol Death Suit
• Deals Rumor Mill: Hewlett Packard, Recordati, Old Mutual
• Greenspoon Marder Picks Up Fla. Health Boutique
• Novartis Leukemia Drug Buyers Blast 'Sham' Patent Suit
• UT Immunology Prof Claims School Forced Her Out Over Age
• Exploring The FDA's Clarification On Biosimilar Labeling
• FTC, Hair Supplement Co. Duel For Quick Wins In False Ad Suit
• CytRx Hit With 2nd Investor Suit Over Cancer Drug Trial
• NJ Arbitration Agreements: It's All In The Language
• GSK, Alphabet Join Forces With $712M Bioelectronics Venture
• BigLaw's (Crowded) Passage To India?